Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) shares were down 4.7% on Tuesday . The stock traded as low as $9.84 and last traded at $9.75. Approximately 1,159 shares traded hands during mid-day trading, a decline of 81% from the average daily volume of 6,180 shares. The stock had previously closed at $10.23.
Pharming Group Price Performance
The firm has a 50-day moving average price of $10.69 and a two-hundred day moving average price of $9.45. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.76 and a quick ratio of 2.00.
Pharming Group (NASDAQ:PHAR - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.03. The business had revenue of $79.09 million during the quarter, compared to analyst estimates of $67.74 million. Pharming Group had a negative return on equity of 6.01% and a negative net margin of 4.14%. As a group, sell-side analysts predict that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current year.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its holdings in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) by 8.6% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 52,147 shares of the company's stock after buying an additional 4,150 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.08% of Pharming Group worth $557,000 at the end of the most recent reporting period. 0.03% of the stock is currently owned by institutional investors and hedge funds.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Further Reading
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access